December 18, 2017 / 12:15 PM / a year ago

BRIEF-US FDA Accepts Regulatory Submission For Tagrisso (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

Dec 18 (Reuters) - Astrazeneca Plc:

* US FDA ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO (OSIMERTINIB) IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below